IPO-bound Intar­cia hauls in $215M, and plans to add more; Pelo­ton rais­es $52M round

With its high­ly tout­ed di­a­betes drug/de­vice IT­CA 650 be­ing set up for a promised launch late next year (if it’s ap­proved), Intar­cia has come up with a $215 mil­lion raise. And the pri­vate biotech, ex­pect­ed to line up for an IPO soon, says it will add even more cash to the kit­ty lat­er this year. IT­CA 650 is an im­plant­ed de­vice that slow­ly oozes a re­for­mu­lat­ed ver­sion of ex­e­natide. The biotech uni­corn has al­ready raised about a bil­lion dol­lars.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.